← FormularyTracking · Category 2

Peptide · Body Protection Compound

BPC-157

Soft-tissue & gut recovery

Status
On watchlist — not yet prescribable

Mechanism

BPC-157 is a synthetic 15-amino-acid peptide derived from a protective protein found in gastric juice. It promotes angiogenesis via VEGF upregulation, accelerates tendon-to-bone healing, and has demonstrated gastroprotective effects in animal models. It appears to modulate nitric oxide signaling and growth hormone receptor expression.

Indications

→Tendon and ligament repair
→Gut mucosal healing (IBD, leaky gut models)
→Muscle injury recovery
→Anti-inflammatory effects

Regulatory status

BPC-157 was moved to the FDA 503A Category 2 bulk substances list in 2023, making it ineligible for routine compounding. HHS has signaled intent to review reclassification. Northline does not prescribe Category 2 substances. Members are first notified on any FDA ruling.

References

01Sikiric P, et al. Stable gastric pentadecapeptide BPC 157. Curr Pharm Des. 2018.
02FDA 503A Category 2 — currently ineligible for compounding.

This fact sheet is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Compounded medications are not FDA-approved. Prescribing decisions are made by a licensed clinician based on individual medical necessity. Not all patients qualify.